00010462572024Q312/31falsehttp://fasb.org/us-gaap/2024#AccountsPayableCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#AccountsPayableCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent342xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesingr:segmentxbrli:pureiso4217:KRWiso4217:ARSiso4217:USDutr:buutr:MMBTUingr:metric00010462572024-01-012024-09-3000010462572024-11-0600010462572024-07-012024-09-3000010462572023-07-012023-09-3000010462572023-01-012023-09-3000010462572024-09-3000010462572023-12-310001046257us-gaap:CommonStockMember2023-12-310001046257us-gaap:AdditionalPaidInCapitalMember2023-12-310001046257us-gaap:TreasuryStockCommonMember2023-12-310001046257us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001046257us-gaap:RetainedEarningsMember2023-12-310001046257us-gaap:NoncontrollingInterestMember2023-12-310001046257us-gaap:RetainedEarningsMember2024-01-012024-09-300001046257us-gaap:NoncontrollingInterestMember2024-01-012024-09-300001046257us-gaap:TreasuryStockCommonMember2024-01-012024-09-300001046257us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001046257us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001046257us-gaap:CommonStockMember2024-09-300001046257us-gaap:AdditionalPaidInCapitalMember2024-09-300001046257us-gaap:TreasuryStockCommonMember2024-09-300001046257us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001046257us-gaap:RetainedEarningsMember2024-09-300001046257us-gaap:NoncontrollingInterestMember2024-09-300001046257us-gaap:CommonStockMember2022-12-310001046257us-gaap:AdditionalPaidInCapitalMember2022-12-310001046257us-gaap:TreasuryStockCommonMember2022-12-310001046257us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001046257us-gaap:RetainedEarningsMember2022-12-310001046257us-gaap:NoncontrollingInterestMember2022-12-3100010462572022-12-310001046257us-gaap:RetainedEarningsMember2023-01-012023-09-300001046257us-gaap:NoncontrollingInterestMember2023-01-012023-09-300001046257us-gaap:TreasuryStockCommonMember2023-01-012023-09-300001046257us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001046257us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001046257us-gaap:CommonStockMember2023-09-300001046257us-gaap:AdditionalPaidInCapitalMember2023-09-300001046257us-gaap:TreasuryStockCommonMember2023-09-300001046257us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001046257us-gaap:RetainedEarningsMember2023-09-300001046257us-gaap:NoncontrollingInterestMember2023-09-3000010462572023-09-300001046257ingr:PurecircleLimitedMember2024-01-012024-09-300001046257ingr:PurecircleLimitedMember2023-12-310001046257ingr:PurecircleLimitedMember2024-09-300001046257ingr:PurecircleLimitedMember2023-07-012023-09-300001046257ingr:PurecircleLimitedMember2022-12-310001046257ingr:PurecircleLimitedMember2023-09-300001046257us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberingr:SouthKoreaDivestitureMember2024-02-010001046257us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberingr:SouthKoreaDivestitureMember2024-02-012024-02-010001046257us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberingr:SouthKoreaDivestitureMember2024-01-012024-03-310001046257us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberingr:SouthKoreaDivestitureMember2024-07-012024-09-300001046257us-gaap:OperatingSegmentsMemberingr:TextureAndHealthfulSolutionsSegmentMember2023-12-310001046257us-gaap:OperatingSegmentsMemberingr:FoodAndIndustrialIngredientsLATAMSegmentMember2023-12-310001046257us-gaap:OperatingSegmentsMemberingr:FoodAndIndustrialIngredientsU.S.CanadaSegmentMember2023-12-310001046257us-gaap:MaterialReconcilingItemsMember2023-12-310001046257us-gaap:OperatingSegmentsMemberingr:TextureAndHealthfulSolutionsSegmentMember2024-01-012024-09-300001046257us-gaap:OperatingSegmentsMemberingr:FoodAndIndustrialIngredientsLATAMSegmentMember2024-01-012024-09-300001046257us-gaap:OperatingSegmentsMemberingr:FoodAndIndustrialIngredientsU.S.CanadaSegmentMember2024-01-012024-09-300001046257us-gaap:MaterialReconcilingItemsMember2024-01-012024-09-300001046257us-gaap:OperatingSegmentsMemberingr:TextureAndHealthfulSolutionsSegmentMember2024-09-300001046257us-gaap:OperatingSegmentsMemberingr:FoodAndIndustrialIngredientsLATAMSegmentMember2024-09-300001046257us-gaap:OperatingSegmentsMemberingr:FoodAndIndustrialIngredientsU.S.CanadaSegmentMember2024-09-300001046257us-gaap:MaterialReconcilingItemsMember2024-09-3000010462572024-07-012024-07-0100010462572024-04-012024-06-300001046257ingr:ArgentinaJointVentureMember2024-01-012024-09-3000010462572023-12-1200010462572023-12-130001046257ingr:CornCommodityMember2024-09-300001046257ingr:CornCommodityMember2023-12-310001046257ingr:NaturalGasCommodityMember2024-09-300001046257ingr:NaturalGasCommodityMember2023-12-310001046257us-gaap:ForeignExchangeContractMemberus-gaap:ShortMemberus-gaap:NondesignatedMember2024-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:ShortMemberus-gaap:NondesignatedMember2023-12-310001046257us-gaap:ForeignExchangeContractMemberus-gaap:LongMemberus-gaap:NondesignatedMember2024-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:LongMemberus-gaap:NondesignatedMember2023-12-310001046257us-gaap:ForeignExchangeContractMemberus-gaap:ShortMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:ShortMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001046257us-gaap:ForeignExchangeContractMemberus-gaap:LongMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:LongMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001046257us-gaap:CommodityContractMemberus-gaap:CashFlowHedgingMember2024-09-300001046257us-gaap:CommodityContractMemberus-gaap:CashFlowHedgingMember2023-12-310001046257us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2024-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2023-12-310001046257us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2023-12-310001046257us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2024-09-300001046257us-gaap:CashFlowHedgingMember2024-09-300001046257us-gaap:CashFlowHedgingMember2023-12-310001046257us-gaap:CommodityContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberingr:AccountsReceivableNetMember2024-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberingr:AccountsReceivableNetMember2024-09-300001046257ingr:AccountsReceivableNetMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300001046257us-gaap:CommodityContractMemberus-gaap:NondesignatedMemberingr:AccountsReceivableNetMember2024-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberingr:AccountsReceivableNetMember2024-09-300001046257ingr:AccountsReceivableNetMemberus-gaap:NondesignatedMember2024-09-300001046257us-gaap:CommodityContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2024-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2024-09-300001046257us-gaap:OtherNoncurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300001046257us-gaap:CommodityContractMemberus-gaap:NondesignatedMemberus-gaap:OtherNoncurrentAssetsMember2024-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:OtherNoncurrentAssetsMember2024-09-300001046257us-gaap:OtherNoncurrentAssetsMemberus-gaap:NondesignatedMember2024-09-300001046257us-gaap:CommodityContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300001046257us-gaap:DesignatedAsHedgingInstrumentMember2024-09-300001046257us-gaap:CommodityContractMemberus-gaap:NondesignatedMember2024-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2024-09-300001046257us-gaap:NondesignatedMember2024-09-300001046257us-gaap:CommodityContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableMember2024-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableMember2024-09-300001046257us-gaap:AccountsPayableMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300001046257us-gaap:CommodityContractMemberus-gaap:NondesignatedMemberus-gaap:AccountsPayableMember2024-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:AccountsPayableMember2024-09-300001046257us-gaap:AccountsPayableMemberus-gaap:NondesignatedMember2024-09-300001046257us-gaap:CommodityContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-09-300001046257us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300001046257us-gaap:CommodityContractMemberus-gaap:NondesignatedMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-09-300001046257us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:NondesignatedMember2024-09-300001046257us-gaap:CommodityContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberingr:AccountsReceivableNetMember2023-12-310001046257us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberingr:AccountsReceivableNetMember2023-12-310001046257ingr:AccountsReceivableNetMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001046257us-gaap:CommodityContractMemberus-gaap:NondesignatedMemberingr:AccountsReceivableNetMember2023-12-310001046257us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberingr:AccountsReceivableNetMember2023-12-310001046257ingr:AccountsReceivableNetMemberus-gaap:NondesignatedMember2023-12-310001046257us-gaap:CommodityContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2023-12-310001046257us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2023-12-310001046257us-gaap:OtherNoncurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001046257us-gaap:CommodityContractMemberus-gaap:NondesignatedMemberus-gaap:OtherNoncurrentAssetsMember2023-12-310001046257us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:OtherNoncurrentAssetsMember2023-12-310001046257us-gaap:OtherNoncurrentAssetsMemberus-gaap:NondesignatedMember2023-12-310001046257us-gaap:CommodityContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001046257us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001046257us-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001046257us-gaap:CommodityContractMemberus-gaap:NondesignatedMember2023-12-310001046257us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2023-12-310001046257us-gaap:NondesignatedMember2023-12-310001046257us-gaap:CommodityContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableMember2023-12-310001046257us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableMember2023-12-310001046257us-gaap:AccountsPayableMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001046257us-gaap:CommodityContractMemberus-gaap:NondesignatedMemberus-gaap:AccountsPayableMember2023-12-310001046257us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:AccountsPayableMember2023-12-310001046257us-gaap:AccountsPayableMemberus-gaap:NondesignatedMember2023-12-310001046257us-gaap:CommodityContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-12-310001046257us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-12-310001046257us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001046257us-gaap:CommodityContractMemberus-gaap:NondesignatedMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-12-310001046257us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-12-310001046257us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:NondesignatedMember2023-12-310001046257us-gaap:CommodityContractMemberus-gaap:CashFlowHedgingMember2024-07-012024-09-300001046257us-gaap:CommodityContractMemberus-gaap:CashFlowHedgingMember2023-07-012023-09-300001046257us-gaap:CommodityContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2024-07-012024-09-300001046257us-gaap:CommodityContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2023-07-012023-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2024-07-012024-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2023-07-012023-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberingr:NetSalesAndCostOfSalesMember2024-07-012024-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberingr:NetSalesAndCostOfSalesMember2023-07-012023-09-300001046257us-gaap:CashFlowHedgingMember2024-07-012024-09-300001046257us-gaap:CashFlowHedgingMember2023-07-012023-09-300001046257us-gaap:CommodityContractMemberus-gaap:CashFlowHedgingMember2024-01-012024-09-300001046257us-gaap:CommodityContractMemberus-gaap:CashFlowHedgingMember2023-01-012023-09-300001046257us-gaap:CommodityContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2024-01-012024-09-300001046257us-gaap:CommodityContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2023-01-012023-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2024-01-012024-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2023-01-012023-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberingr:NetSalesAndCostOfSalesMember2024-01-012024-09-300001046257us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberingr:NetSalesAndCostOfSalesMember2023-01-012023-09-300001046257us-gaap:CashFlowHedgingMember2024-01-012024-09-300001046257us-gaap:CashFlowHedgingMember2023-01-012023-09-300001046257us-gaap:FairValueMeasurementsRecurringMember2024-09-300001046257us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001046257us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001046257us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001046257us-gaap:FairValueMeasurementsRecurringMember2023-12-310001046257us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001046257us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001046257us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001046257ingr:SeniorNotes2.2PercentDue1june2030Member2023-12-310001046257ingr:SeniorNotes2.2PercentDue1june2030Member2024-09-300001046257ingr:SeniorNotes3.20PercentDueOctober12026Member2024-09-300001046257ingr:SeniorNotes3.20PercentDueOctober12026Member2023-12-310001046257ingr:SeniorNotes3.9PercentDue1june2050Member2023-12-310001046257ingr:SeniorNotes3.9PercentDue1june2050Member2024-09-300001046257ingr:SeniorNotes6.625PercentDue2037Member2023-12-310001046257ingr:SeniorNotes6.625PercentDue2037Member2024-09-300001046257us-gaap:RevolvingCreditFacilityMember2024-09-300001046257us-gaap:RevolvingCreditFacilityMember2023-12-310001046257ingr:OtherLongTermBorrowingsMember2024-09-300001046257ingr:OtherLongTermBorrowingsMember2023-12-310001046257ingr:CommercialPaperProgramMember2024-09-300001046257ingr:CommercialPaperProgramMember2023-12-310001046257ingr:OtherShortTermBorrowingsMember2024-09-300001046257ingr:OtherShortTermBorrowingsMember2023-12-310001046257ingr:CommercialPaperProgramMember2024-01-012024-09-300001046257ingr:CommercialPaperProgramMember2023-01-012023-09-300001046257ingr:CommercialPaperProgramMember2023-01-012023-12-310001046257country:USus-gaap:PensionPlansDefinedBenefitMember2024-07-012024-09-300001046257country:USus-gaap:PensionPlansDefinedBenefitMember2023-07-012023-09-300001046257us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-07-012024-09-300001046257us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-07-012023-09-300001046257country:USus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-09-300001046257country:USus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-09-300001046257us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-09-300001046257us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-09-300001046257country:USus-gaap:PensionPlansDefinedBenefitMember2024-09-300001046257us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-09-300001046257us-gaap:PostemploymentRetirementBenefitsMember2024-07-012024-09-300001046257us-gaap:PostemploymentRetirementBenefitsMember2023-07-012023-09-300001046257us-gaap:PostemploymentRetirementBenefitsMember2024-01-012024-09-300001046257us-gaap:PostemploymentRetirementBenefitsMember2023-01-012023-09-300001046257ingr:StockRepurchaseProgram2022Member2022-09-260001046257us-gaap:TreasuryStockCommonMember2024-07-012024-09-300001046257us-gaap:TreasuryStockCommonMember2023-07-012023-09-300001046257us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001046257us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001046257us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001046257us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001046257us-gaap:RestrictedStockUnitsRSUMemberingr:EmployeeMember2024-07-012024-09-300001046257us-gaap:RestrictedStockUnitsRSUMemberingr:EmployeeMember2023-07-012023-09-300001046257us-gaap:RestrictedStockUnitsRSUMemberingr:EmployeeMember2024-01-012024-09-300001046257us-gaap:RestrictedStockUnitsRSUMemberingr:EmployeeMember2023-01-012023-09-300001046257ingr:PerformanceSharesAndOtherShareBasedAwardsMember2024-07-012024-09-300001046257ingr:PerformanceSharesAndOtherShareBasedAwardsMember2023-07-012023-09-300001046257ingr:PerformanceSharesAndOtherShareBasedAwardsMember2024-01-012024-09-300001046257ingr:PerformanceSharesAndOtherShareBasedAwardsMember2023-01-012023-09-3000010462572023-01-012023-12-310001046257us-gaap:EmployeeStockOptionMember2024-09-300001046257us-gaap:RestrictedStockUnitsRSUMemberingr:EmployeeMember2023-12-310001046257us-gaap:RestrictedStockUnitsRSUMemberingr:EmployeeMember2024-09-300001046257us-gaap:PerformanceSharesMember2024-01-012024-09-300001046257ingr:PerformanceSharesVestingBasedOnTSRMember2024-01-012024-09-300001046257ingr:PerformanceSharesVestingBasedOnAdjustedROICMember2024-01-012024-09-300001046257ingr:PerformanceSharesVestingBasedOnTSRMembersrt:MinimumMember2024-01-012024-09-300001046257ingr:PerformanceSharesVestingBasedOnTSRMembersrt:MaximumMember2024-01-012024-09-300001046257ingr:PerformanceSharesVestingBasedOnAdjustedROICMembersrt:MinimumMember2024-01-012024-09-300001046257ingr:PerformanceSharesVestingBasedOnAdjustedROICMembersrt:MaximumMember2024-01-012024-09-300001046257us-gaap:PerformanceSharesMember2024-09-300001046257us-gaap:PerformanceSharesMemberingr:A2021AwardsMember2024-02-012024-02-290001046257us-gaap:PerformanceSharesMemberingr:A2022AwardsMember2024-01-012024-09-300001046257us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310001046257us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310001046257us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310001046257us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-09-300001046257us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-09-300001046257us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-09-300001046257us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300001046257us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-09-300001046257us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-09-300001046257us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001046257us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310001046257us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310001046257us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-09-300001046257us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-09-300001046257us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-09-300001046257us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300001046257us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-09-300001046257us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-09-300001046257us-gaap:RetainedEarningsMember2024-01-012024-03-310001046257us-gaap:NoncontrollingInterestMember2024-01-012024-03-3100010462572024-01-012024-03-310001046257us-gaap:TreasuryStockCommonMember2024-01-012024-03-310001046257us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001046257us-gaap:CommonStockMember2024-03-310001046257us-gaap:AdditionalPaidInCapitalMember2024-03-310001046257us-gaap:TreasuryStockCommonMember2024-03-310001046257us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001046257us-gaap:RetainedEarningsMember2024-03-310001046257us-gaap:NoncontrollingInterestMember2024-03-3100010462572024-03-310001046257us-gaap:RetainedEarningsMember2024-04-012024-06-300001046257us-gaap:NoncontrollingInterestMember2024-04-012024-06-300001046257us-gaap:TreasuryStockCommonMember2024-04-012024-06-300001046257us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001046257us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001046257us-gaap:CommonStockMember2024-06-300001046257us-gaap:AdditionalPaidInCapitalMember2024-06-300001046257us-gaap:TreasuryStockCommonMember2024-06-300001046257us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001046257us-gaap:RetainedEarningsMember2024-06-300001046257us-gaap:NoncontrollingInterestMember2024-06-3000010462572024-06-300001046257us-gaap:RetainedEarningsMember2024-07-012024-09-300001046257us-gaap:NoncontrollingInterestMember2024-07-012024-09-300001046257us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001046257us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001046257us-gaap:RetainedEarningsMember2023-01-012023-03-310001046257us-gaap:NoncontrollingInterestMember2023-01-012023-03-3100010462572023-01-012023-03-310001046257us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001046257us-gaap:TreasuryStockCommonMember2023-01-012023-03-310001046257us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001046257us-gaap:CommonStockMember2023-03-310001046257us-gaap:AdditionalPaidInCapitalMember2023-03-310001046257us-gaap:TreasuryStockCommonMember2023-03-310001046257us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001046257us-gaap:RetainedEarningsMember2023-03-310001046257us-gaap:NoncontrollingInterestMember2023-03-3100010462572023-03-310001046257us-gaap:RetainedEarningsMember2023-04-012023-06-300001046257us-gaap:NoncontrollingInterestMember2023-04-012023-06-3000010462572023-04-012023-06-300001046257us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001046257us-gaap:TreasuryStockCommonMember2023-04-012023-06-300001046257us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001046257us-gaap:CommonStockMember2023-06-300001046257us-gaap:AdditionalPaidInCapitalMember2023-06-300001046257us-gaap:TreasuryStockCommonMember2023-06-300001046257us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001046257us-gaap:RetainedEarningsMember2023-06-300001046257us-gaap:NoncontrollingInterestMember2023-06-3000010462572023-06-300001046257us-gaap:RetainedEarningsMember2023-07-012023-09-300001046257us-gaap:NoncontrollingInterestMember2023-07-012023-09-300001046257us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001046257us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001046257us-gaap:OperatingSegmentsMemberingr:TextureAndHealthfulSolutionsSegmentMember2024-07-012024-09-300001046257us-gaap:OperatingSegmentsMemberingr:FoodAndIndustrialIngredientsLATAMSegmentMember2024-07-012024-09-300001046257us-gaap:OperatingSegmentsMemberingr:FoodAndIndustrialIngredientsU.S.CanadaSegmentMember2024-07-012024-09-300001046257us-gaap:MaterialReconcilingItemsMember2024-07-012024-09-300001046257ingr:OperatingSegmentsAndCorporateNonSegmentMember2024-07-012024-09-300001046257us-gaap:IntersegmentEliminationMemberingr:TextureAndHealthfulSolutionsSegmentMember2024-07-012024-09-300001046257us-gaap:IntersegmentEliminationMemberingr:FoodAndIndustrialIngredientsLATAMSegmentMember2024-07-012024-09-300001046257us-gaap:IntersegmentEliminationMemberingr:FoodAndIndustrialIngredientsU.S.CanadaSegmentMember2024-07-012024-09-300001046257ingr:EliminationsAndReconcilingItemsMember2024-07-012024-09-300001046257us-gaap:IntersegmentEliminationMember2024-07-012024-09-300001046257ingr:TextureAndHealthfulSolutionsSegmentMember2024-07-012024-09-300001046257ingr:FoodAndIndustrialIngredientsLATAMSegmentMember2024-07-012024-09-300001046257ingr:FoodAndIndustrialIngredientsU.S.CanadaSegmentMember2024-07-012024-09-300001046257ingr:CorporateReconcilingItemsAndEliminationsMember2024-07-012024-09-300001046257us-gaap:OperatingSegmentsMemberingr:TextureAndHealthfulSolutionsSegmentMember2023-07-012023-09-300001046257us-gaap:OperatingSegmentsMemberingr:FoodAndIndustrialIngredientsLATAMSegmentMember2023-07-012023-09-300001046257us-gaap:OperatingSegmentsMemberingr:FoodAndIndustrialIngredientsU.S.CanadaSegmentMember2023-07-012023-09-300001046257us-gaap:MaterialReconcilingItemsMember2023-07-012023-09-300001046257ingr:OperatingSegmentsAndCorporateNonSegmentMember2023-07-012023-09-300001046257us-gaap:IntersegmentEliminationMemberingr:TextureAndHealthfulSolutionsSegmentMember2023-07-012023-09-300001046257us-gaap:IntersegmentEliminationMemberingr:FoodAndIndustrialIngredientsLATAMSegmentMember2023-07-012023-09-300001046257us-gaap:IntersegmentEliminationMemberingr:FoodAndIndustrialIngredientsU.S.CanadaSegmentMember2023-07-012023-09-300001046257ingr:EliminationsAndReconcilingItemsMember2023-07-012023-09-300001046257us-gaap:IntersegmentEliminationMember2023-07-012023-09-300001046257ingr:TextureAndHealthfulSolutionsSegmentMember2023-07-012023-09-300001046257ingr:FoodAndIndustrialIngredientsLATAMSegmentMember2023-07-012023-09-300001046257ingr:FoodAndIndustrialIngredientsU.S.CanadaSegmentMember2023-07-012023-09-300001046257ingr:CorporateReconcilingItemsAndEliminationsMember2023-07-012023-09-300001046257ingr:OperatingSegmentsAndCorporateNonSegmentMember2024-01-012024-09-300001046257us-gaap:IntersegmentEliminationMemberingr:TextureAndHealthfulSolutionsSegmentMember2024-01-012024-09-300001046257us-gaap:IntersegmentEliminationMemberingr:FoodAndIndustrialIngredientsLATAMSegmentMember2024-01-012024-09-300001046257us-gaap:IntersegmentEliminationMemberingr:FoodAndIndustrialIngredientsU.S.CanadaSegmentMember2024-01-012024-09-300001046257ingr:EliminationsAndReconcilingItemsMember2024-01-012024-09-300001046257us-gaap:IntersegmentEliminationMember2024-01-012024-09-300001046257ingr:TextureAndHealthfulSolutionsSegmentMember2024-01-012024-09-300001046257ingr:FoodAndIndustrialIngredientsLATAMSegmentMember2024-01-012024-09-300001046257ingr:FoodAndIndustrialIngredientsU.S.CanadaSegmentMember2024-01-012024-09-300001046257ingr:CorporateReconcilingItemsAndEliminationsMember2024-01-012024-09-300001046257us-gaap:OperatingSegmentsMemberingr:TextureAndHealthfulSolutionsSegmentMember2023-01-012023-09-300001046257us-gaap:OperatingSegmentsMemberingr:FoodAndIndustrialIngredientsLATAMSegmentMember2023-01-012023-09-300001046257us-gaap:OperatingSegmentsMemberingr:FoodAndIndustrialIngredientsU.S.CanadaSegmentMember2023-01-012023-09-300001046257us-gaap:MaterialReconcilingItemsMember2023-01-012023-09-300001046257ingr:OperatingSegmentsAndCorporateNonSegmentMember2023-01-012023-09-300001046257us-gaap:IntersegmentEliminationMemberingr:TextureAndHealthfulSolutionsSegmentMember2023-01-012023-09-300001046257us-gaap:IntersegmentEliminationMemberingr:FoodAndIndustrialIngredientsLATAMSegmentMember2023-01-012023-09-300001046257us-gaap:IntersegmentEliminationMemberingr:FoodAndIndustrialIngredientsU.S.CanadaSegmentMember2023-01-012023-09-300001046257ingr:EliminationsAndReconcilingItemsMember2023-01-012023-09-300001046257us-gaap:IntersegmentEliminationMember2023-01-012023-09-300001046257ingr:TextureAndHealthfulSolutionsSegmentMember2023-01-012023-09-300001046257ingr:FoodAndIndustrialIngredientsLATAMSegmentMember2023-01-012023-09-300001046257ingr:FoodAndIndustrialIngredientsU.S.CanadaSegmentMember2023-01-012023-09-300001046257ingr:CorporateReconcilingItemsAndEliminationsMember2023-01-012023-09-300001046257us-gaap:CorporateNonSegmentMember2024-07-012024-09-300001046257us-gaap:CorporateNonSegmentMember2023-07-012023-09-300001046257us-gaap:CorporateNonSegmentMember2024-01-012024-09-300001046257us-gaap:CorporateNonSegmentMember2023-01-012023-09-3000010462572022-01-012022-12-310001046257country:BRus-gaap:ForeignCountryMemberus-gaap:ReductionInTaxesMember2024-09-300001046257country:BRus-gaap:ForeignCountryMemberus-gaap:ReductionInTaxesMember2023-12-310001046257country:BRus-gaap:ForeignCountryMemberus-gaap:AccountsReceivableMemberus-gaap:ReductionInTaxesMember2024-09-300001046257country:BRus-gaap:ForeignCountryMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:ReductionInTaxesMember2024-09-300001046257ingr:RobRitchieMember2024-01-012024-09-300001046257ingr:RobRitchieMember2024-07-012024-09-300001046257ingr:RobRitchieMember2024-09-300001046257ingr:JamesD.GrayMember2024-01-012024-09-300001046257ingr:JamesD.GrayMember2024-07-012024-09-300001046257ingr:JamesD.GrayMember2024-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
(Mark One)
| | | | | | | | |
| x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2024
or
| | | | | | | | |
| o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number 1-13397
INGREDION INCORPORATED
(Exact name of registrant as specified in its charter)
| | | | | |
Delaware | 22-3514823 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| |
5 Westbrook Corporate Center, Westchester, Illinois | 60154 |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (708) 551-2600
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Common Stock, par value $0.01 per share | | INGR | | New York Stock Exchange |
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | | | | | | |
Large accelerated filer | x | Accelerated filer | o |
| | | |
Non-accelerated filer | o | Smaller reporting company | o |
| | | |
| | Emerging growth company | o |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date.
| | | | | | | | |
Class | | Outstanding at November 6, 2024 |
Common Stock, $0.01 par value | | 65,157,632 shares |
| | |
|
INGREDION INCORPORATED
FORM 10-Q
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Ingredion Incorporated
Condensed Consolidated Statements of Income
(Unaudited)
(dollars and shares in millions, except per share amounts)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended September 30, | | Nine Months Ended September 30, |
| | 2024 | | 2023 | | 2024 | | 2023 |
Net sales | | $ | 1,870 | | | $ | 2,033 | | | $ | 5,630 | | | $ | 6,239 | |
Cost of sales | | 1,391 | | | 1,612 | | | 4,288 | | | 4,890 | |
Gross profit | | 479 | | | 421 | | | 1,342 | | | 1,349 | |
Operating expenses | | 198 | | | 203 | | | 578 | | | 578 | |
Other operating expense (income), net | | 1 | | | (5) | | | 5 | | | 6 | |
Restructuring/impairment charges | | 12 | | | 10 | | | 38 | | | 10 | |
Operating income | | 268 | | | 213 | | | 721 | | | 755 | |
Financing costs | | 1 | | | 26 | | | 30 | | | 88 | |
Net gain on sale of business | | (8) | | | — | | | (90) | | | — | |
Other non-operating expense | | 2 | | | 2 | | | 2 | | | 4 | |
Income before income taxes | | 273 | | | 185 | | | 779 | | | 663 | |
Provision for income taxes | | 84 | | | 25 | | | 222 | | | 145 | |
Net income | | 189 | | | 160 | | | 557 | | | 518 | |
Less: Net income attributable to non-controlling interests | | 1 | | | 2 | | | 5 | | | 6 | |
Net income attributable to Ingredion | | $ | 188 | | | $ | 158 | | | $ | 552 | | | $ | 512 | |
| | | | | | | | |
Earnings per common share attributable to Ingredion common shareholders: | | | | | | | | |
| | | | | | | | |
Weighted average common shares outstanding: | | | | | | | | |
Basic | | 65.3 | | 66.0 | | 65.6 | | 66.1 |
Diluted | | 66.5 | | 67.0 | | 66.6 | | 67.1 |
| | | | | | | | |
Earnings per common share of Ingredion: | | | | | | | | |
Basic | | $ | 2.88 | | | $ | 2.39 | | | $ | 8.41 | | | $ | 7.75 | |
Diluted | | $ | 2.83 | | | $ | 2.36 | | | $ | 8.29 | | | $ | 7.63 | |
See the Notes to the Condensed Consolidated Financial Statements.
Ingredion Incorporated
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
(dollars in millions)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended September 30, | | Nine Months Ended September 30, |
| | 2024 | | 2023 | | 2024 | | 2023 |
Net income | | $ | 189 | | | $ | 160 | | | $ | 557 | | | $ | 518 | |
Other comprehensive income: | | | | | | | | |
Gains (losses) on cash flow hedges, net of income tax effect of $1, $1, $17 and $32 | | 6 | | | (5) | | | (45) | | | (91) | |
Losses on cash flow hedges reclassified to earnings, net of income tax effect of $8, $10, $25 and $11 | | 20 | | | 24 | | | 67 | | | 25 | |
(Losses) gains on pension and other postretirement obligations, net of income tax effect of $—, $—, $— and $1 | | (1) | | | — | | | 1 | | | (1) | |
Losses related to pension and other postretirement obligations reclassified to earnings, net of income tax effect of $— | | 1 | | | 1 | | | 1 | | | 1 | |
Currency translation adjustment | | 92 | | | (45) | | | 32 | | | (30) | |
Comprehensive income | | 307 | | | 135 | | | 613 | | | 422 | |
Less: Comprehensive income (loss) attributable to non-controlling interests | | 3 | | | 2 | | | 6 | | | (2) | |
Comprehensive income attributable to Ingredion | | $ | 304 | | | $ | 133 | | | $ | 607 | | | $ | 424 | |
See the Notes to the Condensed Consolidated Financial Statements.
Ingredion Incorporated
Condensed Consolidated Balance Sheets
(dollars and shares in millions, except per share amounts)
| | | | | | | | | | | | | | |
| | September 30, 2024 | | December 31, 2023 |
| | (Unaudited) | |
Assets | | | | |
Current assets: | | | | |
Cash and cash equivalents | | $ | 877 | | | $ | 401 | |
Short-term investments | | 7 | | | 8 | |
Accounts receivable, net | | 1,173 | | | 1,279 | |
Inventories | | 1,234 | | | 1,450 | |
Prepaid expenses and assets held for sale | | 60 | | | 261 | |
Total current assets | | 3,351 | | | 3,399 | |
Property, plant and equipment, net of accumulated depreciation of $3,532 and $3,428 | | 2,332 | | | 2,370 | |
Intangible assets, net of accumulated amortization of $322 and $299 | | 1,295 | | | 1,303 | |
Other non-current assets | | 547 | | | 570 | |
Total assets | | $ | 7,525 | | | $ | 7,642 | |
| | | | |
Liabilities and stockholders' equity | | | | |
Current liabilities: | | | | |
Short-term borrowings | | $ | 99 | | | $ | 448 | |
Accounts payable | | 604 | | | 778 | |
Accrued liabilities and liabilities held for sale | | 552 | | | 546 | |
Total current liabilities | | 1,255 | | | 1,772 | |
Long-term debt | | 1,741 | | | 1,740 | |
Other non-current liabilities | | 499 | | | 480 | |
Total liabilities | | 3,495 | | | 3,992 | |
| | | | |
Share-based payments subject to redemption | | 54 | | | 55 | |
Redeemable non-controlling interests | | 7 | | | 43 | |
| | | | |
Ingredion stockholders’ equity: | | | | |
Preferred stock — authorized 25.0 shares — $0.01 par value, none issued | | — | | | — | |
Common stock — authorized 200.0 shares — $0.01 par value, 77.8 shares issued at September 30, 2024 and December 31, 2023 | | 1 | | | 1 | |
Additional paid-in capital | | 1,145 | | | 1,146 | |
Less: Treasury stock (common stock: 12.7 and 12.6 shares at September 30, 2024 and December 31, 2023) at cost | | (1,245) | | | (1,207) | |
Accumulated other comprehensive loss | | (1,000) | | | (1,056) | |
Retained earnings | | 5,049 | | | 4,654 | |
Total Ingredion stockholders’ equity | | 3,950 | | | 3,538 | |
Non-redeemable non-controlling interests | | 19 | | | 14 | |
Total stockholders’ equity | | 3,969 | | | 3,552 | |
Total liabilities and stockholders’ equity | | $ | 7,525 | | | $ | 7,642 | |
See the Notes to the Condensed Consolidated Financial Statements.
Ingredion Incorporated
Condensed Consolidated Statements of Equity and Redeemable Equity
(Unaudited)
(dollars in millions)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Total Equity | | Share-based Payments Subject to Redemption | | Redeemable Non- Controlling Interests |
| | Preferred Stock | | Common Stock | | Additional Paid-In Capital | | Treasury Stock | | Accumulated Other Comprehensive Loss | | Retained Earnings | | Non- Redeemable Non- Controlling Interests | | |
Balance as of December 31, 2023 | | $ | — | | | $ | 1 | | | $ | 1,146 | | | $ | (1,207) | | | $ | (1,056) | | | $ | 4,654 | | | $ | 14 | | | $ | 55 | | | $ | 43 | |
Net income attributable to Ingredion | | — | | | — | | | — | | | — | | | — | | | 552 | | | — | | | — | | | — | |
Net income (loss) attributable to non-controlling interests | | — | | | — | | | — | | | — | | | — | | | — | | | 7 | | | — | | | (2) | |
Dividends declared | | — | | | — | | | — | | | — | | | — | | | (157) | | | (3) | | | — | | | — | |
Repurchases of common stock, net | | — | | | — | | | — | | | (87) | | | — | | | — | | | — | | | — | | | — | |
| | | | | | | | | | | | | | | | | | |
Share-based compensation, net of issuance | | — | | | — | | | 5 | | | 49 | | | — | | | — | | | — | | | (1) | | | — | |
Fair market value adjustment to non-controlling interests | | — | | | — | | | (6) | | | — | | | — | | | — | | | — | | | — | | | 6 | |
Purchases of non-controlling interests | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (40) | |
Other comprehensive income | | — | | | — | | | — | | | — | | | 56 | | | — | | | 1 | | | — | | | — | |
| | | | | | | | | | | | | | | | | | |
Balance as of September 30, 2024 | | $ | — | | | $ | 1 | | | $ | 1,145 | | | $ | (1,245) | | | $ | (1,000) | | | $ | 5,049 | | | $ | 19 | | | $ | 54 | | | $ | 7 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Total Equity | | Share-based Payments Subject to Redemption | | Redeemable Non- Controlling Interests |
| | Preferred Stock | | Common Stock | | Additional Paid-In Capital | | Treasury Stock | | Accumulated Other Comprehensive Loss | | Retained Earnings | | Non- Redeemable Non- Controlling Interests | | |
Balance as of December 31, 2022 | | $ | — | | | $ | 1 | | | $ | 1,132 | | | $ | (1,148) | | | $ | (1,048) | | | $ | 4,210 | | | $ | 16 | | | $ | 48 | | | $ | 51 | |
Net income attributable to Ingredion | | — | | | — | | | — | | | — | | | — | | | 512 | | | — | | | — | | | — | |
Net income attributable to non-controlling interests | | — | | | — | | | — | | | — | | | — | | | — | | | 6 | | | — | | | — | |
Dividends declared | | — | | | — | | | — | | | — | | | — | | | (147) | | | (2) | | | — | | | — | |
Repurchases of common stock, net | | — | | | — | | | — | | | (101) | | | — | | | — | | | — | | | — | | | — | |
Share-based compensation, net of issuance | | — | | | — | | | 4 | | | 38 | | | — | | | — | | | — | | | 1 | | | — | |
Fair market value adjustment to non-controlling interests | | — | | | — | | | 7 | | | — | | | — | | | — | | | — | | | — | | | (7) | |
Purchases of non-controlling interests | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (2) | |
Other comprehensive (loss) | | — | | | — | | | — | | | — | | | (96) | | | — | | | (7) | | | — | | | (1) | |
Balance as of September 30, 2023 | | $ | — | | | $ | 1 | | | $ | 1,143 | | | $ | (1,211) | | | $ | (1,144) | | | $ | 4,575 | | | $ | 13 | | | $ | 49 | | | $ | 41 | |
See the Notes to the Condensed Consolidated Financial Statements.
Ingredion Incorporated
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(dollars in millions)
| | | | | | | | | | | | | | |
| | Nine Months Ended September 30, |
| | 2024 | | 2023 |
Cash from operating activities | | | | |
Net income | | $ | 557 | | | $ | 518 | |
Non-cash charges to net income: | | | | |
Depreciation and amortization | | 160 | | | 165 | |
Mechanical stores expense | | 45 | | | 48 | |
Net gain on sale of business | | (90) | | | — | |
Deferred income taxes | | 19 | | | (7) | |
Impairment charges | | 26 | | | 10 | |
Other non-cash charges | | 26 | | | 42 | |
Changes in working capital: | | | | |
Accounts receivable and prepaid expenses | | 113 | | | (6) | |
Inventories | | 229 | | | 61 | |
Accounts payable and accrued liabilities | | (94) | | | (173) | |
Margin accounts | | 7 | | | 2 | |
Other | | 2 | | | (13) | |
Cash provided by operating activities | | 1,000 | | | 647 | |
Cash from investing activities | | | | |
Capital expenditures and mechanical stores purchases | | (170) | | | (233) | |
Proceeds from disposal of manufacturing facilities and properties | | — | | | 2 | |
Proceeds from sale of business | | 255 | | | — | |
| | | | |
Other | | (6) | | | (11) | |
Cash provided by (used for) investing activities | | 79 | | | (242) | |
Cash from financing activities | | | | |
Proceeds from borrowings | | 527 | | | 636 | |
Payments on debt | | (539) | | | (652) | |
Commercial paper borrowings, net | | (327) | | | (57) | |
Repurchases of common stock, net | | (87) | | | (101) | |
Issuances of common stock for share-based compensation, net | | 21 | | | 18 | |
Purchases of non-controlling interests | | (40) | | | (2) | |
Dividends paid, including to non-controlling interests | | (156) | | | (143) | |
Cash (used for) financing activities | | (601) | | | (301) | |
Effects of foreign exchange rate changes on cash and cash equivalents | | (2) | | | (5) | |
Increase in cash and cash equivalents | | 476 | | | 99 | |
Cash and cash equivalents, beginning of period | | 401 | | | 236 | |
Cash and cash equivalents, end of period | | $ | 877 | | | $ | 335 | |
See the Notes to the Condensed Consolidated Financial Statements.
Ingredion Incorporated
Notes to Condensed Consolidated Financial Statements
(dollars in millions, except per share data, unless otherwise noted)
1. Basis of Presentation and New Accounting Standards
Unless the context otherwise requires, all references herein to the “Company,” “Ingredion,” “we,” “us,” and “our” shall mean Ingredion Incorporated and its consolidated subsidiaries. These statements should be read in conjunction with the consolidated financial statements and the related notes to those statements contained in Ingredion’s Annual Report on Form 10-K for the year ended December 31, 2023. The significant accounting policies and estimates used in preparing these Condensed Consolidated Financial Statements were applied on the same basis consistent with those reflected in Ingredion’s Annual Report on Form 10-K for the year ended December 31, 2023.
The unaudited Condensed Consolidated Financial Statements as of September 30, 2024 and for the third quarter and year-to-date September 30, 2024 and 2023 included herein were prepared by us on the same basis as our audited Consolidated Financial Statements for the year ended December 31, 2023 and reflect all adjustments (consisting solely of normal recurring items unless otherwise noted) that are, in our opinion, necessary for the fair presentation of the Condensed Consolidated Statements of Income, Condensed Consolidated Statements of Comprehensive Income, Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Equity and Redeemable Equity, and Condensed Consolidated Statements of Cash Flows. The results for the interim period are not necessarily indicative of the results expected for the full year or any other future period.
Effective January 1, 2024, there are three reportable segments consisting of Texture & Healthful Solutions (“T&HS”), Food & Industrial Ingredients - Latin America (“F&II - LATAM”) and Food & Industrial Ingredients - U.S./Canada (“F&II - U.S./Canada”).
New Accounting Standards
In September 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations. This ASU requires filers to disclose information about supplier finance programs that is sufficient to allow financial statement users to understand their nature, activity during the period, changes from period to period and potential magnitude. This ASU is effective for annual periods beginning after December 15, 2022, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023. We adopted this ASU at the beginning of our 2023 fiscal year and adopted the amendment on rollforward information at the beginning of our 2024 fiscal year. The disclosures required by this ASU are reflected in Note 12.
In August 2023, the FASB issued ASU No. 2023-05, Business Combinations - Joint Venture Formations (Subtopic 805-60). This ASU requires that a joint venture apply a new basis of accounting upon formation. By applying a new basis of accounting, a joint venture, upon formation, will recognize and initially measure its assets and liabilities at fair value (with exceptions to fair value measurement that are consistent with the business combinations guidance). This ASU is effective prospectively for all joint venture formations with a formation date on or after January 1, 2025. A joint venture that was formed before January 1, 2025 may elect to apply the amendments retrospectively. We will adopt this ASU on a prospective basis at the beginning of our 2025 fiscal year and do not believe it will have a material impact on the Condensed Consolidated Financial Statements.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280). This ASU improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. This ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. Entities must apply the amendments in this ASU retrospectively to all prior periods presented in the financial statements. We are currently assessing the impact of this ASU on the Condensed Consolidated Financial Statements.
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires public business entities on an annual basis to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. Additionally, this ASU requires information pertaining to taxes paid (net of refunds received) to be disaggregated by federal, state, and foreign taxes with further disaggregation for specific jurisdictions to the extent the related amounts exceed a quantitative
Ingredion Incorporated
Notes to Condensed Consolidated Financial Statements
(dollars in millions, except per share data, unless otherwise noted)
threshold. The ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. We are currently waiting for additional guidance to be issued on the quantitative thresholds before we can assess the impact of this ASU on the Condensed Consolidated Financial Statements.
2. Acquisitions and Divestitures
PureCircle Non-Controlling Interests Acquisition
During year-to-date 2024, we purchased shares from minority shareholders in PureCircle Limited (“PureCircle”) for $40 million, which increased our ownership percentage from 88 percent as of December 31, 2023 to 98 percent as of September 30, 2024.
During the third quarter of 2023, we purchased shares from minority shareholders in PureCircle for $2 million. These purchases increased our ownership percentage from 87 percent as of December 31, 2022 to 88 percent as of September 30, 2023.
South Korea Divestiture
On February 1, 2024, we completed the sale of our South Korea business, which we reported in All Other for segment purposes, for a total consideration of 384.0 billion South Korean won, or approximately $294 million. We received 330.0 billion South Korea won, or $247 million net of certain transaction costs, when the transaction closed, and we will receive the remaining consideration in equal annual payments through February 2027. As a result, we recognized a pre-tax net gain of $90 million consisting of $82 million during the first quarter of 2024 and an $8 million working capital true-up during the three months ended September 30, 2024 within Net gain on sale of business in the Condensed Consolidated Statements of Income.
3. Intangible Assets
Goodwill represents the excess of the cost of an acquired entity over the fair value assigned to identifiable assets acquired and liabilities assumed.
The original carrying value of goodwill by reportable segment and All Other as of September 30, 2024 is presented below. There were no accumulated impairment charges by reportable segment.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | T&HS | | F&II - LATAM | | F&II - U.S./Canada | | All Other | | Total |
| | | | | | | | | | |
| | | | | | | | | | |
Balance as of January 1, 2024 | | $ | 388 | | | $ | 146 | | | $ | 296 | | | $ | 88 | | | $ | 918 | |
| | | | | | | | | | |
Cumulative translation adjustment | | 5 | | | (2) | | | — | | | 4 | | | 7 | |
Balance as of September 30, 2024 | | $ | 393 | | | $ | 144 | | | $ | 296 | | | $ | 92 | | | $ | 925 | |
Ingredion assesses goodwill and indefinite-lived intangible assets for impairment annually (or more frequently if impairment indicators arise). Based on the results of our assessment as of July 1, 2024, there were no impairments in our goodwill or indefinite-lived intangible assets. Our indefinite-lived intangible assets balance was $143 million as of each of September 30, 2024 and December 31, 2023.
Ingredion Incorporated
Notes to Condensed Consolidated Financial Statements
(dollars in millions, except per share data, unless otherwise noted)
4. Investments
Investments as of September 30, 2024 and December 31, 2023 are as follows:
| | | | | | | | | | | | | | |
| | September 30, 2024 | | December 31, 2023 |
Equity investments | | $ | 34 | | | $ | 27 | |
Equity method investments | | 94 | | | 112 | |
Marketable securities | | 5 | | | 4 | |
Total investments | | $ | 133 | | | $ | 143 | |
Our investments classified as equity investments do not have readily determinable fair values. Beginning on the dates we entered into the agreements for equity method investments, our share of income or loss from these investments is included within Other operating expense (income), net in the Condensed Consolidated Statements of Income. During the second quarter of 2024, we recorded $18 million in Restructuring/impairment charges in the Condensed Consolidated Statements of Income, which represented an other-than-temporary impairment on our equity method investments.
Argentina Joint Venture
On February 12, 2021, we entered into an agreement with an affiliate of Grupo Arcor, an Argentine food company, to establish Ingrear Holding S.A. (the “Argentina joint venture”), a joint venture to sell value-added ingredients to customers in the food, beverage, pharmaceutical and other industries in Argentina, Chile and Uruguay. Ingredion and Grupo Arcor completed all closing conditions to combine the manufacturing facilities, finalize the transaction and formally establish the Argentina joint venture, which is managed by a jointly appointed team of executives. During the quarter, we received antitrust clearance, subject to fulfillment of certain conditions to promote arms-length competition in the Argentina corn wet milling market, which must be completed by September 2029. The Argentina joint venture is accounted for on the equity method of accounting, and we recognize our share of income or expense in Other operating expense one month in arrears due to the timing of when results are available. On December 13, 2023, the new Argentine government allowed the Argentine peso to devalue from the exchange rate of approximately 366 pesos to one U.S. dollar, to 800 pesos to one U.S. dollar. As we recognize our share of earnings one month in arrears, the loss from the change in value of the peso in December 2023 was recorded in Other operating expense (income), net during the first quarter of 2024.
5. Derivative Instruments and Hedging Activities
Commodity price hedging: We had outstanding futures and option contracts that hedged the forecasted purchase of approximately 59 million and 109 million bushels of corn as of September 30, 2024 and December 31, 2023. We also had outstanding swap contracts that hedged the forecasted purchase of approximately 28 million mmbtus of natural gas as of both September 30, 2024 and December 31, 2023.
Foreign currency hedging: We hedge certain assets using foreign currency derivatives not designated as hedging instruments, which had a notional value of $489 million and $694 million as of September 30, 2024 and December 31, 2023. We also hedge certain liabilities using foreign currency derivatives not designated as hedging instruments, which had a notional value of $147 million and $182 million as of September 30, 2024 and December 31, 2023.
We hedge certain assets using foreign currency cash flow hedging instruments, which had a notional value of $394 million and $449 million as of September 30, 2024 and December 31, 2023. We also hedge certain liability positions using foreign currency cash flow hedging instruments, which had a notional value of $483 million and $621 million as of September 30, 2024 and December 31, 2023.
Interest rate hedging: We periodically enter into T-Locks to hedge our exposure to interest rate changes. We have settled T-Locks associated with the issuance of our senior notes due in 2030 and 2050. The realized loss upon settlement of these T-Locks was recorded in Accumulated other comprehensive loss (“AOCL”) and is amortized into earnings over the term of the senior notes. We did not have outstanding T-Locks as of either September 30, 2024 or December 31, 2023.
Ingredion Incorporated
Notes to Condensed Consolidated Financial Statements
(dollars in millions, except per share data, unless otherwise noted)
The derivative instruments designated as cash flow hedges included in AOCL as of September 30, 2024 and December 31, 2023 are as follows:
| | | | | | | | | | | | | | |
| | (Losses) gains included in AOCL as of |
| | September 30, 2024 | | December 31, 2023 |
Commodity contracts, net of income tax effect of $12 and $17 | | $ | (34) | | | $ | (46) | |
Foreign currency contracts, net of income tax effect of $4 and $1 | | 10 | | | — | |
Interest rate contracts, net of income tax effect of $1 | | (2) | | | (2) | |
Total | | $ | (26) | | | $ | (48) | |
As of September 30, 2024, AOCL included $25 million of net losses (net of income taxes of $9 million) on commodities-related derivative instruments, T-Locks and foreign currency hedges designated as cash flow hedges that are expected to be reclassified into earnings during the next twelve months.
The fair value and balance sheet location of our derivative instruments, presented gross in the Condensed Consolidated Balance Sheets, are as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Fair Value of Hedging Instruments as of September 30, 2024 |
| | Designated Hedging Instruments | | Non-Designated Hedging Instruments |
| | Commodity Contracts | | Foreign Currency Contracts | | Total | | Commodity Contracts | | Foreign Currency Contracts | | Total |
Accounts receivable, net | | $ | 6 | | | $ | 12 | | | $ | 18 | | | $ | — | | | $ | 6 | | | $ | 6 | |
Other non-current assets | | 1 | | | 5 | | | 6 | | | — | | | — | | | — | |
Assets | | 7 | | | 17 | | | 24 | | | — | | | 6 | | | 6 | |
Accounts payable | | 27 | | | 3 | | | 30 | | | 1 | | | 7 | | | 8 | |
Other non-current liabilities | | 1 | | | 3 | | | 4 | | | — | | | — | | | — | |
Liabilities | | 28 | | | 6 | | | 34 | | | 1 | | | 7 | | | 8 | |
Net Assets/(Liabilities) | | $ | (21) | | | $ | 11 | | | $ | (10) | | | $ | (1) | | | $ | (1) | | | $ | (2) | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Fair Value of Hedging Instruments as of December 31, 2023 |
| | Designated Hedging Instruments | | Non-Designated Hedging Instruments |
| | Commodity Contracts | | Foreign Currency Contracts | | Total | | Commodity Contracts | | Foreign Currency Contracts | | Total |
Accounts receivable, net | | $ | 6 | | | $ | 11 | | | $ | 17 | | | $ | — | | | $ | 5 | | | $ | 5 | |
Other non-current assets | | — | | 4 | | 4 | | — | | — | | | — | |
Assets | | 6 | | 15 | | 21 | | — | | 5 | | 5 |
Accounts payable | | 44 | | 14 | | 58 | | 2 | | 12 | | 14 |
Other non-current liabilities | | 2 | | 2 | | 4 | | — | | — | | | — | |
Liabilities | | 46 | | 16 | | 62 | | 2 | | 12 | | 14 |
Net Assets/(Liabilities) | | $ | (40) | | | $ | (1) | | | $ | (41) | | | $ | (2) | | | $ | (7) | | | $ | (9) | |
Ingredion Incorporated
Notes to Condensed Consolidated Financial Statements
(dollars in millions, except per share data, unless otherwise noted)
Additional information relating to our derivative instruments in cash flow hedging relationships is as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | (Losses) Gains Recognized in AOCL on Derivatives | | | | (Losses) Gains Reclassified from AOCL into Income |
| | Three Months Ended September 30, | | Income Statement | | Three Months Ended September 30, |
| | 2024 | | 2023 | | Location | | 2024 | | 2023 |
Commodity contracts | | $ | (5) | | | $ | (10) | | | Cost of sales | | $ | (28) | | | $ | (37) | |
Foreign currency contracts | | 12 | | | 4 | | | Net sales/Cost of sales | | — | | | 3 | |
Total | | $ | 7 | | | $ | (6) | | | | | $ | (28) | | | $ | (34) | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | (Losses) Gains Recognized in AOCL on Derivatives | | | | (Losses) Gains Reclassified from AOCL into Income |
| | Nine Months Ended September 30, | | Income Statement | | Nine Months Ended September 30, |
| | 2024 | | 2023 | | Location | | 2024 | | 2023 |
Commodity contracts | | $ | (76) | | | $ | (132) | | | Cost of sales | | $ | (93) | | | $ | (46) | |
Foreign currency contracts | | 14 | | | 9 | | | Net sales/Cost of sales | | 1 | | | 10 | |
Total | | $ | (62) | | | $ | (123) | | | | | $ | (92) | | | $ | (36) | |
6. Fair Value Measurements
We measure certain assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. In determining fair value, we use various valuation approaches. The hierarchy of those valuation approaches is in three levels based on the reliability of inputs. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Below is a summary of the hierarchy levels:
•Level 1 inputs consist of quoted prices (unadjusted) in active markets for identical assets or liabilities.
•Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. Level 2 inputs are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are observable for the asset or liability or can be derived principally from or corroborated by observable market data.
•Level 3 inputs are unobservable inputs for the asset or liability. Unobservable inputs are used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.
Assets and liabilities measured at fair value on a recurring basis are presented below:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | As of September 30, 2024 | | As of December 31, 2023 |
| | Total | | Level 1 | | Level 2 | | Level 3 | | Total | | Level 1 | | Level 2 | | Level 3 |
Marketable securities | | $ | 5 | | | $ | 5 | | | $ | — | | | $ | — | | | $ | 4 | | | $ | 4 | | | $ | — | | | $ | — | |
Derivative assets | | 30 | | | 29 | | | 1 | | | — | | | 26 | | | 26 | | | — | | | — | |
Derivative liabilities | | 42 | | | 31 | | | 11 | | | — | | | 76 | | | 43 | | | 33 | | | — | |
Long-term debt | | 1,657 | | | — | | | 1,657 | | | — | | | 1,591 | | | — | | | 1,591 | | | — | |
The carrying values of cash equivalents, short-term investments, accounts receivable, short-term borrowings and accounts payable approximate fair values. Commodity futures, options and swap contracts are recognized at fair value. Foreign currency forward contracts, swaps and options are also recognized at fair value. The fair value of our Long-term debt is estimated based on quotations of major securities dealers who are market makers in the securities.
Ingredion Incorporated
Notes to Condensed Consolidated Financial Statements
(dollars in millions, except per share data, unless otherwise noted)
7. Financing Arrangements
Debt carrying amounts, net of related discounts, premiums and debt issuance costs, are presented below:
| | | | | | | | | | | | | | |
| | As of September 30, 2024 | | As of December 31, 2023 |
2.900% senior notes due June 1, 2030 | | $ | 597 | | | $ | 596 | |
3.200% senior notes due October 1, 2026 | | 499 | | | 499 | |
3.900% senior notes due June 1, 2050 | | 391 | | | 391 | |
6.625% senior notes due April 15, 2037 | | 252 | | | 253 | |
| | | | |
Revolving credit agreement | | — | | | — | |
Other long-term borrowings | | 2 | | | 1 | |
Total long-term debt | | 1,741 | | | 1,740 | |
Commercial paper | | — | | | 327 | |
Other short-term borrowings | | 99 | | | 121 | |
Total short-term borrowings | | 99 | | | 448 | |
Total debt | | $ | 1,840 | | | $ | 2,188 | |
We maintain a commercial paper program under which we may issue senior unsecured notes of short-term maturities up to a maximum aggregate principal amount of $1.0 billion outstanding at any time. The notes may be sold from time to time on customary terms in the U.S. commercial paper market. We use the note proceeds for general corporate purposes. During year-to-date 2024, the average amount of commercial paper outstanding was $41 million with an average interest rate of 5.51 percent and a weighted average maturity of eight days. During year-to-date 2023, the average amount of commercial paper outstanding was $438 million with an average interest rate of 5.25 percent and a weighted average maturity of eleven days. As of September 30, 2024, we had no commercial paper outstanding. As of December 31, 2023, $327 million of commercial paper was outstanding with an average interest rate of 5.50 percent and a weighted average maturity of eleven days. The amount of commercial paper outstanding under this program for the remainder of 2024 may fluctuate.
Other short-term borrowings as of September 30, 2024 and December 31, 2023 primarily include amounts outstanding under various unsecured local country operating lines of credit.
8. Pension and Other Post-employment Benefits
Components of net periodic cost consist of the following for the periods presented:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended September 30, | | Nine Months Ended September 30, |
| | U.S. Plans | | Non-U.S. Plans | | U.S. Plans | | Non-U.S. Plans |
| | 2024 | | 2023 | | 2024 | | 2023 | | 2024 | | 2023 | | 2024 | | 2023 |
Service cost | | $ | — | | | $ | 1 | | | $ | 1 | | | $ | 1 | | | $ | 2 | | | $ | 2 | | | $ | 2 | | | $ | 3 | |
Interest cost | | 4 | | | 3 | | | 2 | | | 3 | | | 11 | | | 11 | | | 7 | | | 8 | |
Expected return on plan assets | | (4) | | | (4) | | | (2) | | | (3) | | | (13) | | | (12) | | | (6) | | | (7) | |
Amortization of prior service credit | | — | | | (1) | | | — | | | — | | | — | | | (1) | | | — | | | — | |
Amortization of actuarial loss | | — | | | 1 | | | — | | | 1 | | | — | | | 1 | | | — | | | 1 | |
Net periodic cost (a) | | $ | — | | | $ | — | | | $ | 1 | | | $ | 2 | | | $ | — | | | $ | 1 | | | $ | 3 | | | $ | 5 | |
We anticipate that we will make cash contributions of $1 million and $4 million to the U.S. and non-U.S. pension plans in 2024. For the year-to-date 2024, we made cash contributions of $1 million to the U.S. pension plans and $3 million to the non-U.S. pension plans.
Ingredion Incorporated
Notes to Condensed Consolidated Financial Statements
(dollars in millions, except per share data, unless otherwise noted)
The following table sets forth the components of net postretirement benefit cost for the periods presented:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended September 30, | | Nine Months Ended September 30, |
| | 2024 | | 2023 | | 2024 | | 2023 |
| | | | | | | | |
Interest cost | | $ | 2 | | | $ | 1 | | | $ | 3 | | | $ | 3 | |
| | | | | | | | |
Amortization of prior service cost | | 1 | | | — | | | 1 | | | — | |
Net periodic cost (a) | | $ | 3 | | | $ | 1 | | | $ | 4 | | | $ | 3 | |
_______________________________________
(a)The service cost component of net periodic cost is presented within either Cost of sales or Operating expenses on the Condensed Consolidated Statements of Income. The interest cost, expected return on plan assets, amortization of prior service costs and amortization of actuarial losses are presented within Other non-operating expense on the Condensed Consolidated Statements of Income.
9. Equity
Treasury Stock: On September 26, 2022, the Board of Directors approved a stock repurchase program authorizing us to purchase up to 6.0 million shares of our outstanding common stock until December 31, 2025. We may repurchase shares from time to time in the open market, in privately negotiated transactions, or otherwise, at prices we deem appropriate. We are not obligated to repurchase any shares under the authorization, and the repurchase program may be suspended, discontinued, or modified at any time, for any reason and without notice. The parameters of our stock repurchase program are not established solely with reference to the dilutive impact of shares issued under our stock incentive plan. However, we expect that, over time, share repurchases will offset the dilutive impact of shares issued under the stock incentive plan.
During the third quarter and year-to-date 2024, we repurchased 185 thousand and 762 thousand outstanding shares of common stock in open market transactions at a net cost of $21 million and $87 million. During the third quarter and year-to-date 2023, we repurchased 1.0 million outstanding shares of common stock in open market transactions at a net cost of $101 million.
Ingredion Incorporated
Notes to Condensed Consolidated Financial Statements
(dollars in millions, except per share data, unless otherwise noted)
Share-based Payments: Share-based compensation expense for the periods presented is as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended September 30, | | Nine Months Ended September 30, |
| | 2024 | | 2023 | | 2024 | | 2023 |
Stock options: | | | | | | | | |
Pre-tax compensation expense | | $ | 1 | | | $ | 1 | | | $ | 4 | | | $ | 3 | |
Income tax benefit | | — | | | — | | | — | | | — | |
Stock option expense, net of income taxes | | 1 | | | 1 | | | 4 | | | 3 | |
| | | | | | | | |
Restricted stock units (“RSUs”): | | | | | | | | |
Pre-tax compensation expense | | 4 | | | 4 | | | 15 | | | 11 | |
Income tax benefit | | (1) | | | — | | | (2) | | | (1) | |
RSUs, net of income taxes | | 3 | | | 4 | | | 13 | | | 10 | |
| | | | | | | | |
Performance shares and other share-based awards: | | | | | | | | |
Pre-tax compensation expense | | 3 | | | 4 | | | 11 | | | 9 | |
Income tax benefit | | — | | | (1) | | | — | | | (1) | |
Performance shares and other share-based compensation expense, net of income taxes | | 3 | | | 3 | | | 11 | | | 8 | |
| | | | | | | | |
Total share-based compensation: | | | | | | | | |
Pre-tax compensation expense | | 8 | | | 9 | | | 30 | | | 23 | |
Income tax benefit | | (1) | | | (1) | | | (2) | | | (2) | |
Total share-based compensation expense, net of income taxes | | $ | 7 | | | $ | 8 | | | $ | 28 | | | $ | 21 | |
Stock Options: Under our stock incentive plan, stock options are granted at exercise prices that equal the market value of the underlying common stock on the date of grant. The options have a ten-year term and are exercisable upon vesting, which occurs over a three-year period at the anniversary dates of the date of grant. We generally recognize compensation expense on a straight-line basis for all awards over the employee’s vesting period. We estimate a forfeiture rate at the time of grant and update the estimate throughout the vesting period of the stock options within the amount of compensation costs recognized in each period.
We granted non-qualified options to purchase 178 thousand shares and 197 thousand shares for year-to-date 2024 and 2023. We estimated the fair value of each option grant by using the Black-Scholes option-pricing model with the following assumptions:
| | | | | | | | | | | | | | |
| | Nine Months Ended September 30, |
| | 2024 | | 2023 |
Expected life (in years) | | 5.5 | | 5.5 |
Risk-free interest rate | | 4.2% | | 4.0% |
Expected volatility | | 28.1% | | 28.3% |
Expected dividend yield | | 2.9% | | 2.9% |
The expected life of options represents the weighted average period that we expect options granted to be outstanding giving consideration to vesting schedules and our historical exercise patterns. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the grant date for the period corresponding to the expected life of the options. Expected volatility is based on historical volatilities of our common stock, and dividend yields are based on our dividend yield at the date of issuance.
Ingredion Incorporated
Notes to Condensed Consolidated Financial Statements
(dollars in millions, except per share data, unless otherwise noted)
Stock option activity for year-to-date 2024 is as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Number of Options (in thousands) | | Weighted Average Exercise Price per Share | | Average Remaining Contractual Term (in years) | | Aggregate Intrinsic Value |
Outstanding as of December 31, 2023 | | 1,953 | | $ | 96.61 | | | 5.0 | | $ | 29 | |
Granted | | 178 | | 108.38 | | | | | |
Exercised | | (390) | | 85.17 | | | | | |
Cancelled | | (44) | | 101.45 | | | | | |
Outstanding as of September 30, 2024 | | 1,697 | | $ | 100.35 | | | 5.3 | | $ | 63 | |
Exercisable as of September 30, 2024 | | 1,347 | | $ | 100.13 | | | 4.5 | | $ | 50 | |
For year-to-date 2024, cash received from the exercise of stock options was approximately $33 million. As of September 30, 2024, the unrecognized compensation cost related to non-vested stock options totaled $2 million, which we expect to amortize over the weighted-average period of approximately 1.7 years.
Additional information pertaining to stock option activity is as follows:
| | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended September 30, | Nine Months Ended September 30, |
| | 2024 | | 2023 | 2024 | | 2023 |
Weighted average grant date fair value of stock options granted (per share) | | $ | — | | | $ | — | | $ | 26.33 | | | $ | 23.80 | |
Total intrinsic value of stock options exercised | | 3 | | | 1 | | 13 | | | 11 | |
Restricted Stock Units: We have granted restricted stock units (“RSUs”) to certain key employees. The RSUs are primarily subject to cliff vesting, generally after three years, provided the employee remains in our service. The fair value of the RSUs is determined based upon the number of shares granted and the quoted market price of our common stock at the grant date.
The following table summarizes RSU activity year-to-date in 2024:
| | | | | | | | | | | | | | |
| | Number of Restricted Shares (in thousands) | | Weighted Average Fair Value per Share |
Non-vested as of December 31, 2023 | | 552 | | $ | 92.05 | |
Granted | | 210 | | 108.81 | |
Vested | | (174) | | 87.46 | |
Cancelled | | (45) | | 95.74 | |
Non-vested as of September 30, 2024 | | 543 | | $ | 99.43 | |
As of September 30, 2024, the total remaining unrecognized compensation cost related to RSUs was $23 million, which will be amortized on a weighted-average basis over approximately 1.8 years.
Performance Shares: We have a long-term incentive plan for senior management in the form of performance shares. The vesting of the performance shares is generally based on two performance metrics. Fifty percent of the performance shares awarded vest based on our total shareholder return as compared to the total shareholder return of our peer group, and the remaining fifty percent vest based on the calculation of our three-year average Adjusted Return on Invested Capital (“Adjusted ROIC”) against an established ROIC target.
Ingredion Incorporated
Notes to Condensed Consolidated Financial Statements
(dollars in millions, except per share data, unless otherwise noted)
For the 2024 performance shares awarded based on our total shareholder return, the number of shares that ultimately vest can range from zero to 200 percent of the grant depending on our total shareholder return as compared to the total shareholder return of our peer group. The share award vesting will be calculated at the end of the three-year period and is subject to approval by management and the People, Culture, and Compensation Committee (“Compensation Committee”) of the Board of Directors. Compensation expense is based on the fair value of the performance shares at the grant date, established using a Monte Carlo simulation model. We amortize the total compensation expense for these awards over a three-year graded vesting schedule.
For the 2024 performance shares awarded based on Adjusted ROIC, the number of shares that ultimately vest can range from zero to 200 percent of the grant depending on our Adjusted ROIC performance against the target. The share award vesting will be calculated at the end of the three-year period and is subject to approval by management and the Compensation Committee. We base compensation expense on the market price of our common stock on the grant date and the final number of shares that ultimately vest. We estimate the potential share vesting at least annually to adjust the compensation expense for these awards over the vesting period to reflect our estimated Adjusted ROIC performance against the target. We amortize the total compensation expense for these awards over a three-year graded vesting schedule.
For year-to-date 2024, we awarded 86 thousand performance shares at a weighted average fair value of $127.97 per share. As of September 30, 2024, the unrecognized compensation cost related to these awards was $11 million, which we will amortize over the remaining service period of 2.0 years. The 2021 performance share awards that vested in February 2024 achieved a 200 percent payout of the granted performance shares. As of September 30, 2024, we estimated the 2022 performance share awards will pay out at 200 percent. For year-to-date 2024, 17 thousand shares were cancelled.
Accumulated Other Comprehensive Loss: The following is a summary of accumulated other comprehensive loss for year-to-date 2024 and 2023:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Cumulative Translation Adjustment | | Hedging Activities | | Pension and Other Post-employment Benefits | | AOCL |
Balance as of December 31, 2023 | | $ | (961) | | | $ | (48) | | | $ | (47) | | | $ | (1,056) | |
Other comprehensive income (loss) before reclassification adjustments | | 32 | | | (62) | | | 1 | | | (29) | |
Loss reclassified from AOCL | | — | | | 92 | | | 1 | | | 93 | |
Tax (provision) | | — | | | (8) | | | — | | | (8) | |
Net other comprehensive income | | 32 | | | 22 | | | 2 | | | 56 | |
Balance as of September 30, 2024 | | $ | (929) | | | $ | (26) | | | $ | (45) | | | $ | (1,000) | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Cumulative Translation Adjustment | | Hedging Activities | | Pension and Other Post-employment Benefits | | AOCL |
Balance as of December 31, 2022 | | $ | (1,008) | | | $ | 6 | | | $ | (46) | | | $ | (1,048) | |
Other comprehensive (loss) before reclassification adjustments | | (30) | | | (123) | | | (2) | | | (155) | |
Loss reclassified from AOCL | | — | | | 36 | | | 1 | | | 37 | |
Tax benefit | | — | | | 21 | | | 1 | | | 22 | |
Net other comprehensive (loss) | | (30) | | | (66) | | | — | | | (96) | |
Balance as of September 30, 2023 | | $ | (1,038) | | | $ | (60) | | | $ | (46) | | | $ | (1,144) | |
Ingredion Incorporated
Notes to Condensed Consolidated Financial Statements
(dollars in millions, except per share data, unless otherwise noted)
Supplemental Information: The following Condensed Consolidated Statements of Equity and Redeemable Equity present information about the dividends per share for common stock for the periods indicated:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Total Equity | | Share-based Payments Subject to Redemption | | Redeemable Non- Controlling Interests |
| | Preferred Stock | | Common Stock | | Additional Paid-In Capital | | Treasury Stock | | Accumulated Other Comprehensive Loss | | Retained Earnings | | Non-Redeemable Non-Controlling Interests | | |
Balance as of December 31, 2023 | | $ | — | |